Germany
· Delayed Price · Currency is EUR Genomtec Statistics
Total Valuation
Genomtec has a market cap or net worth of EUR 16.06 million. The enterprise value is 14.81 million.
| Market Cap | 16.06M |
| Enterprise Value | 14.81M |
Important Dates
The last earnings date was Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 15.06M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +13.49% |
| Shares Change (QoQ) | +1.92% |
| Owned by Insiders (%) | 9.00% |
| Owned by Institutions (%) | 3.32% |
| Float | 12.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4,568.64 |
| PB Ratio | 6.62 |
| P/TBV Ratio | 6.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.74 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.82, with a Debt / Equity ratio of 0.21.
| Current Ratio | 2.82 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -73.38 |
Financial Efficiency
Return on equity (ROE) is -111.03% and return on invested capital (ROIC) is -54.29%.
| Return on Equity (ROE) | -111.03% |
| Return on Assets (ROA) | -40.36% |
| Return on Invested Capital (ROIC) | -54.29% |
| Return on Capital Employed (ROCE) | -84.46% |
| Revenue Per Employee | 135 |
| Profits Per Employee | -99,231 |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -17,108 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.38% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -34.38% |
| 50-Day Moving Average | 1.16 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 33.31 |
| Average Volume (20 Days) | 21 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomtec had revenue of EUR 3,515 and -2.58 million in losses. Loss per share was -0.17.
| Revenue | 3,515 |
| Gross Profit | -1.90M |
| Operating Income | -2.55M |
| Pretax Income | -2.60M |
| Net Income | -2.58M |
| EBITDA | -1.91M |
| EBIT | -2.55M |
| Loss Per Share | -0.17 |
Balance Sheet
The company has 1.73 million in cash and 499,175 in debt, giving a net cash position of 1.24 million.
| Cash & Cash Equivalents | 1.73M |
| Total Debt | 499,175 |
| Net Cash | 1.24M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.43M |
| Book Value Per Share | 0.16 |
| Working Capital | 1.42M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -72,406.51% |
| Pretax Margin | -73,886.63% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genomtec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.49% |
| Shareholder Yield | -13.49% |
| Earnings Yield | -16.07% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Genomtec has an Altman Z-Score of 7.12 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.12 |
| Piotroski F-Score | 2 |